Acute Liver Failure
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Acute Liver Failure is an emerging landscape with 15 programs across 7 companies. The most active players are Steminent Biotherapeutics Inc., Paracrine Therapeutics Dermatology Pte. Ltd., Ocera Therapeutics. 2 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
N-Acetyl-L-Cysteine
Peking University People's Hospital
Granulocyte Colony-Stimulating Factor
Sanofi
Therapeutic Plasma Excahnge
Institute of Liver and Biliary Sciences, India
Prophylactic Antibiotics
Institute of Liver and Biliary Sciences, India
N-Acetylcysteine (NAC) Treatment
The First Affiliated Hospital of Soochow University
Analysis
Modality Breakdown
92%
Small molecule
11 of 12 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 100% of 17 pipeline programs.
Analysis
Trial Status
20
clinical trials
Clinical Trials
Trial Activity
20 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)